Fertin Pharma A/S (“Fertin Pharma”), a leading developer and manufacturer of innovative pharmaceutical and well-being products based on oral and intra-oral delivery systems, today announced the closing of its acquisition by Philip Morris International Inc. (PMI) (NYSE: PM) for an enterprise value of DKK 5.1 billion (approximately USD 820 million[1] ). “We are excited to